Highest-materiality recent filing
DSS enters $1M loan with related party Alset; note convertible at $0.45, warrants at $0.50
$1M loan from Alset (related party under common control of Chairman Chan Heng Fai).
DSS enters $2.45M convertible note and warrant deal with related party Alset International
Loan of $2,450,000 via convertible promissory note at 3% simple interest.
DSS converts $12M Impact Biomedical debt into 31.9M shares of Impact common stock
DSS settled all outstanding debt owed by Impact Biomedical under a $12M original note and amendments.
DSS restates 2023 10-K; $23.5M overstatement of deconsolidation loss, discontinued ops omitted
Audit Committee determined 2023 10-K financials unreliable due to errors; restated via 10-K/A filed Oct 22, 2024.
CEO Frank Heuszel to step down; Jason Grady appointed interim CEO
Frank Heuszel resigns as CEO effective Aug 23, 2024; no disagreement with company on operations, policies, or practices.
DSS amends $12.86M promissory note with Impact BioMedical, extends maturity to 2030
Principal balance funded to $12,859,328.60, including $1,231,483.14 interest funding advanced Jan 17, 2024.
DSS Inc. effects 1-for-20 reverse stock split, reducing shares from 140M to ~7M
Reverse stock split at 1-for-20 ratio effective January 4, 2024; begins split-adjusted trading Jan 5.
DSS receives NYSE American low-price delisting notice; must cure by Apr 20, 2024
Received letter from NYSE American on Oct 20, 2023, citing low share price for substantial period.
DSS settles Maiden Biosciences lawsuit for $8.75M; case dismissed with prejudice
Settlement payment of $8,750,000 made on February 10, 2023.
DSS and affiliates face $14.2M judgment in Maiden lawsuit; intends to appeal
Jury verdict for Maiden; judgment entered Dec 20, 2022: principal $4.24M, prejudgment interest $514,735, post-judgment interest $146,810, plus costs and fees.
DSS receives NYSE American notice for late Form 10-Q filing; faces potential delisting
Received NYSE American notice on Aug 23, 2022 for failing to timely file Q2 2022 Form 10-Q.
DSS, Inc. will restate FY2021 financials due to $2.1M inventory overstatement
Audit Committee determines FY2021 financial statements cannot be relied upon; restatement of 10-K planned.
DSS issues 21.4M shares to acquire $8.72M convertible note from affiliate
DSS issued 21,366,177 shares of common stock to acquire a convertible note from Alset International Limited (AI), an affiliate.
On July 7, 2022, DSS issued 17,570,948 shares to Alset EHome International Inc. (AEI) as part of the True Partner Transaction.
DSS reduces AEI share purchase to $1.5M; agrees to acquire 62.1M True Partner shares
DSS amended Jan 25 SPA with AEI: AEI to buy 3,986,877 shares for $1,519,000, down from 44,619,423 shares for $17M.
DSS to acquire convertible promissory note from Alset for $8.7M payable in 21.4M shares
DSS to purchase an $8.35M principal note (plus $367,400 accrued interest) issued by American Medical REIT, Inc.
DSS agrees to sell up to 44.6M shares at $0.381/share for $17M to Alset EHome
Up to 44,619,423 shares of common stock at $0.3810 per share.
DSS issues ~71.4M shares to acquire 25.1% of Alset Intl and True Partner Capital with $1.7B AUM
DSS issued 59,979,582 shares for 877,248,065 ordinary shares of Alset International Limited (25.1% stake).
DSS subsidiary invests $3M in SHRG, acquires 59.6% ownership through shares and warrants
DSS subsidiary Decentralized to invest $3,000,000 for 50M SHRG common shares and 50M warrants at $0.063/share.
Freed Maxick CPAs, P.C. resigned as independent auditor on Dec 2, 2021; Turner, Stone & Company, L.L.P. engaged on Dec 3, 2021.
DSS invests up to $40M in American Pacific Bancorp; APB posts $336K net loss for FY2020
DSS signed SPA to invest up to $40,000,200 for 6,666,700 Class A shares of APB at ~$6.00/share.
DSS subsidiary AMRE acquires three hospitals for $62M; loans $14.7M to fund deal
AMRE acquired hospitals in Fort Worth, TX; Plano, TX; and Pittsburgh, PA for $62 million aggregate.
DSS receives $15M from Alset, invests $40M in American Pacific Bancorp to become majority owner
DSS issues 12,155,591 shares to Alset EHome at $1.234/share for $15M investment.
Mr. Frank D. Heuszel, announced that effective on the close of business on August 23, 2024, he will step down as the Chief Executive Officer
Effective August 23, 2024, the Board of Directors of DSS, Inc. elected Mr. Jason Grady as the Company’s new Interim Chief Executive Officer.
Effective August 23, 2024, the Board of Directors of DSS, Inc. elected Mr. Jason Grady as the Company’s new Interim Chief Executive Officer.
Mr. Frank D. Heuszel, announced that effective on the close of business on August 23, 2024, he will step down as the Chief Executive Officer of DSS.
On February 8, 2024, Sassuan Samson (Sam) Lee notified DSS, Inc. (the “Company”) that he was resigning as a member of the Board of Directors of the Company, effective immediately.
Effective October 2, 2023, the Board of Directors of DSS, Inc. (“DSS” or the “Company”) elected Mr. Danny Lim Sheng Hon, age 31, as a member of the Company’s Board of Directors (the “Board”).
On September 1, 2023, John “JT” Thatch notified DSS, Inc. (the “Company”) that he was resigning as a member of the Board of Directors of the Company, effective August 31, 2023.
Effective July 11, 2022, the Board of the Company elected Ms. Joanne Wong Hiu Pan as an independent, non-executive director of the Board.
Effective July 8, 2022, the Board of Directors of DSS, Inc. (“DSS” or the “Company”) elected Mr. Wong Shui Yeung as a non-executive member of the Company’s Board of Directors (the “Board”).
On August 19, 2021, Lo Wah Wai resigned as a member of the Board of Directors (“Board”) of Document Security Systems, Inc. (the “Company”).
On August 16, 2021, Document Security Systems, Inc. (“DSS” or the “Company”) appointed Mr. Todd Macko as the Chief Financial Officer of the Company.
Max materiality 0.90 · Median 0.55 · Most common event other_material